Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Pharmaceuticals ETF

103.07
+0.82500.81%
Volume:23.29K
Turnover:2.38M
Market Cap:1.69B
PE:9.60
High:103.07
Open:101.86
Low:101.30
Close:102.24
52wk High:108.66
52wk Low:69.02
Shares:16.35M
Float Shares:16.35M
Volume Ratio:0.52
T/O Rate:0.14%
Dividend:1.43
Dividend Rate:1.39%
EPS(TTM):10.74
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

OverviewCompanyNewsFilings

Nvidia Corp., Merck Share Gains Lead Dow's 425-Point Climb

Dow Jones
·
20 hours ago

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients taking Foundayo

TIPRANKS
·
22 hours ago

Top Midday Stories: Paramount Skydance Settles With US States to Pave Way for Warner Bros. Deal; Anthropic Now Eyeing November IPO

MT Newswires Live
·
Yesterday

Novo Nordisk Says New Obesity Drug Outperformed Lilly's Zepbound in Phase 3 Trial

Dow Jones
·
Yesterday

J&J says Caplyta Phase 3 study in bipolar I met primary endpoint

TIPRANKS
·
Yesterday

Novo Stock (NVO) Sinks Despite Beating Eli Lilly in New CagriSema Obesity Trial

TIPRANKS
·
Yesterday

Johnson & Johnson Says Phase 3 Trial Shows Caplyta Cuts Bipolar I Mania Symptoms by Week 3

Reuters
·
Yesterday

J&J - Caplyta Demonstrates Statistically Significant Rapid Reduction in Manic Symptoms at Week 3

THOMSON REUTERS
·
Yesterday

Caplyta® (Lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Pivotal Phase 3 Study

THOMSON REUTERS
·
Yesterday

J&J - Caplyta Well-Tolerated; Dry Mouth and Nausea Most Common Adverse Events

THOMSON REUTERS
·
Yesterday

Oura Files for Initial Public Offering on Nasdaq

MT Newswires Live
·
Yesterday

LIVE Markets-Big Beauty Faces Growing Threat from AI, Smaller Rivals

Reuters
·
Yesterday

Sichuan Biokin Pharmaceutical Says Unit Received $250 Mln Milestone Payment from Bristol-Myers Squibb for Iza-Bren Agreement

THOMSON REUTERS
·
Yesterday

Oura Targets $15.62 Billion Valuation in US IPO, Setting Stage for Fall Listings

Reuters
·
Yesterday

Oura - Eli Lilly Interested in Purchasing up to $100 Mln; Dragoneer up to $300 Mln in IPO - SEC Filing

THOMSON REUTERS
·
Yesterday

Japan Health Ministry Approves Merck’s Keytruda QLEX for Subcutaneous Use Across Keytruda Indications

Reuters
·
Yesterday

Merck’s Keytruda Qlex™ (Pembrolizumab and Berahyaluronidase Alfa-Pmph) Approved in Japan for Subcutaneous Administration for All Keytruda® (Pembrolizumab) Indications Approved in Japan

THOMSON REUTERS
·
Yesterday

Novo Says Its Next-Gen Obesity Drug Tops Lilly Rival in Late-Stage Study

Reuters
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Yesterday

Eli Lilly, Novo sued over risk of sudden vision loss, WSJ reports

TIPRANKS
·
Sep 20
More